C4 Therapeutics (NASDAQ:CCCC) Now Covered by Analysts at Stephens

Research analysts at Stephens assumed coverage on shares of C4 Therapeutics (NASDAQ:CCCC) in a report released on Monday,Briefing.com Automated Import reports. The firm set an “equal weight” rating and a $4.00 price target on the stock. Stephens’ price objective indicates a potential downside of 7.19% from the stock’s current price.

Separately, BMO Capital Markets reiterated an “outperform” rating and issued a $20.00 target price on shares of C4 Therapeutics in a report on Tuesday, August 6th. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $10.00.

C4 Therapeutics Price Performance

Shares of CCCC stock opened at $4.31 on Monday. C4 Therapeutics has a one year low of $1.06 and a one year high of $11.88. The company’s fifty day moving average price is $5.89 and its 200-day moving average price is $5.72. The company has a market capitalization of $304.24 million, a price-to-earnings ratio of -2.54 and a beta of 3.04.

C4 Therapeutics (NASDAQ:CCCC) last announced its quarterly earnings data on Thursday, October 31st. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.05. C4 Therapeutics had a negative net margin of 313.35% and a negative return on equity of 42.45%. The business had revenue of $15.36 million during the quarter, compared to analyst estimates of $5.95 million. Equities research analysts expect that C4 Therapeutics will post -1.48 earnings per share for the current fiscal year.

Hedge Funds Weigh In On C4 Therapeutics

Institutional investors have recently modified their holdings of the stock. Point72 DIFC Ltd purchased a new stake in shares of C4 Therapeutics in the 3rd quarter worth approximately $51,000. Headlands Technologies LLC purchased a new stake in shares of C4 Therapeutics during the second quarter valued at $45,000. Cynosure Group LLC purchased a new position in shares of C4 Therapeutics in the third quarter worth about $57,000. B. Riley Wealth Advisors Inc. purchased a new position in C4 Therapeutics during the 2nd quarter worth approximately $51,000. Finally, Aigen Investment Management LP purchased a new stake in C4 Therapeutics in the third quarter valued at $82,000. 78.81% of the stock is owned by hedge funds and other institutional investors.

About C4 Therapeutics

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.